CA19.9 和 LINC01197 在胰腺癌中的临床意义。
Clinical significance of CA 19.9 and LINC01197 in pancreatic cancer.
机构信息
Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
出版信息
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2358-2367. doi: 10.26355/eurrev_202003_20503.
OBJECTIVE
This study aimed to explore the expression and clinical significance of LINC01197 in serum of patients with pancreatic cancer (PC).
PATIENTS AND METHODS
Fifty PC patients (patient group) treated in our hospital from March 2012 to April 2014 were collected, and another 50 normal people (normal group) were collected for physical examination. The LINC01197 expression in serum of the two groups was detected by qRT-PCR method, and the CA 19.9 expression in serum was detected by Roche automatic biochemistry. The expression and diagnostic value of CA 19.9 and LINC01197 in PC were analyzed, and the relationship between LINC01197 and prognosis of PC patients was observed.
RESULTS
The CA 19.9 expression in the patient group was significantly higher than that in the normal group (p<0.001). Their area under the curve was 0.791 and 0.944 respectively. The incidence of phases III+IV, lymphatic invasion, and distant metastasis in patients with low expression of LINC01197 is significantly higher than that in those with high expression, and has higher diagnostic value. With the progress of clinical staging, the TNM expression decreased gradually and there were differences between groups (p<0.001). Spearman's test analysis found that the decreased TNM staging of LINC01197 increased gradually (r=-0.816, p<0.001), and the area under the curve of LINC01197 distinguishing phase I and phase II+phase+III+phase IV was 0.930. The 1-year survival rate and 5-year survival rate of patients in low expression group were lower than those in high expression group (p1 year =0.037, p5 year =0.014). Distant metastasis is an independent prognostic factor for PC patients to survive for 1 to 5 years. Differentiation, TNM staging, and LINC01197 are independent prognostic factors for PC patients to survive for 5 years.
CONCLUSIONS
The low expression of LINC01197 in PC patients indicates poor prognosis of patients and is expected to be a potential diagnostic and prognostic indicator of PC.
目的
本研究旨在探讨 LINC01197 在胰腺癌（PC）患者血清中的表达及临床意义。
方法
收集我院 2012 年 3 月至 2014 年 4 月收治的 50 例 PC 患者（患者组），另选取同期体检的 50 例正常人（正常组）。采用 qRT-PCR 法检测两组血清中 LINC01197 的表达，采用罗氏全自动生化仪检测血清中 CA19.9 的表达，分析 CA19.9 和 LINC01197 在 PC 中的表达及诊断价值，观察 LINC01197 与 PC 患者预后的关系。
结果
患者组 CA19.9 表达明显高于正常组（p<0.001），其曲线下面积分别为 0.791 和 0.944。LINC01197 低表达患者的 III+IV 期、淋巴侵袭和远处转移发生率明显高于高表达患者，且具有更高的诊断价值。随着临床分期的进展，TNM 表达逐渐降低，组间差异有统计学意义（p<0.001）。Spearman 检验分析发现，LINC01197 的 TNM 分期逐渐降低（r=-0.816，p<0.001），LINC01197 区分 I 期和 II+III+IV 期的曲线下面积为 0.930。低表达组患者 1 年和 5 年生存率均低于高表达组（p1 年=0.037，p5 年=0.014）。远处转移是 PC 患者 1 至 5 年生存的独立预后因素。分化程度、TNM 分期和 LINC01197 是 PC 患者 5 年生存的独立预后因素。
结论
PC 患者 LINC01197 低表达提示患者预后不良，有望成为 PC 的潜在诊断和预后指标。
Zotero 插件